MindWalk Reports Strong Q3 Revenue Growth, Reduced Net Loss, and Extended Cash Runway
Summary
MindWalk Holdings Corp. announced strong Q3 revenue growth of 52% and a significantly reduced net loss, extending its cash runway to over one year, despite identifying a material weakness in internal controls.
Key Events
-
Strong Q3 Financial Performance
Revenue for the three months ended January 31, 2026, increased by 52% to $4.2 million CAD, and the net loss significantly decreased to $3.9 million CAD from $21.5 million CAD in the prior year's comparable period. Basic and diluted loss per share was $(0.08) CAD.
-
Extended Cash Runway
The company reported $14.1 million CAD in cash on hand as of January 31, 2026, which is expected to fund operations for at least one year.
-
ATM Program Utilized
MindWalk sold 533,969 common shares under its At-The-Market (ATM) facility, generating gross proceeds of $1.1 million CAD during the quarter.
-
Material Weakness in Internal Controls
Management identified a material weakness in internal controls over financial reporting due to insufficient resources for complex technical accounting issues, with remediation efforts underway.
Analysis
MindWalk Holdings Corp. reported significant operational improvements in its third quarter, with revenue increasing by 52% to $4.2 million CAD compared to the prior year. The company also substantially reduced its net loss to $3.9 million CAD, down from $21.5 million CAD in the same period last year (which included a large asset impairment). This improved financial performance, coupled with $14.1 million CAD in cash on hand, provides the company with an expected cash runway of at least one year. While the company continues to operate at a net loss and disclosed a material weakness in internal controls over financial reporting, it is actively implementing remediation measures. The company also utilized its At-The-Market (ATM) facility, selling 533,969 common shares for $1.1 million CAD during the quarter, providing additional capital.
At the time of this filing, HYFT was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.8M. The 52-week trading range was $0.32 to $3.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.